Answers are grounded in this paper and cite their sources.
Androgen receptor-targeted treatments for breast cancer are in development and have shown promising preliminary results. In-depth understanding of AR and AR-related signaling pathways would improve the treatment strategies for AR-positive breast cancer. Further preclinical and clinical studies of AR-targeted drugs alone and in combination with other drugs are justified and warranted to clarify the biology of AR and inform the development of AR-targeted therapies to improve survival outcome in patients with breast cancer.
No takes yet. Share an insight, caveat, or question.
Kono et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: